These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 26045797)

  • 21. Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer.
    Nishio M; Goto K; Chikamori K; Hida T; Katakami N; Maemondo M; Ohishi N; Tamura T
    Clin Lung Cancer; 2016 Jan; 17(1):24-9.e1. PubMed ID: 26336854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene mutation characteristics of nonsmall-cell lung carcinoma patients with wild-type epidermal growth factor receptor and sensitivity to Tarceva therapy.
    Cui Y; Xu J; Xin L; Tian Y; Zhan Z; Qi D
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C80-3. PubMed ID: 26323931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
    Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
    Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
    Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
    Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer.
    Lopes GL; Vattimo EF; Castro Junior Gd
    J Bras Pneumol; 2015; 41(4):365-75. PubMed ID: 26398757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience with erlotinib in the treatment of non-small cell lung cancer.
    Landi L; Cappuzzo F
    Ther Adv Respir Dis; 2015 Aug; 9(4):146-63. PubMed ID: 26063687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
    J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.
    Inno A; Di Noia V; Martini M; D'Argento E; Di Salvatore M; Arena V; Schinzari G; Orlandi A; Larocca LM; Cassano A; Barone C
    Pathol Oncol Res; 2019 Apr; 25(2):513-520. PubMed ID: 29557085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient.
    Lozano MD; Labiano T; Zudaire I; Subtil JC; Gúrpide A; Echeveste JI; Zulueta JJ; Martín-Algarra S; Pérez-Gracia JL
    Int J Surg Pathol; 2015 Apr; 23(2):111-5. PubMed ID: 24942894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
    Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
    Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.